FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

<b>STATEMENT</b>	<b>OF CHANGES</b>	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  BOGER JOSHUA S  (Last) (First) (Middle)  C/O VERTEX PHARMACEUTICALS INCORPORATED  130 WAVERLY ST					<u>V</u>	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]  3. Date of Earliest Transaction (Month/Day/Year) 11/02/2011									all applic	cable) or	10% Owr Other (sp below)		wner
					11/										below)				
(Street) CAMBRIDGE MA 02139			- 4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)							Lir		ividual or Joint/Group Filing (Check Appl Form filed by One Reporting Person Form filed by More than One Reporti Person				n		
(City)	(St	•	(Zip)										<u> </u>						
1. Title of Security (Instr. 3) 2. Trans		2. Transac	tion	on 2A. Deemed Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			5. Amou Securitie Benefici Owned I		int of es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
						Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			(Instr. 4)			
Common	Stock			11/02/2	2011				M		4,000	A	\$24.6	6	731	1,395		D	
Common	Stock			11/02/2	2011				S <sup>(1)</sup>		3,100	D	\$37.06	2)(3)	730	),995		D	
Common	Stock			11/02/2	2011				S <sup>(1)</sup>		900	D	\$37.78	3 <sup>(3)(4)</sup> 728,695 D		D			
Common	Stock	k													13	,286		I	401(k)
		T	able I								posed of, , converti			y Oı	wned				
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  3. Transaction Date (Month/Day/Year)		if any	eemed 4. tion Date, Transa Code (n/Day/Year) 8)				6. Date Exerci Expiration Da (Month/Day/Y		ate Amount of		of es ng /e Security	De Se	Price of crivative ecurity estr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owne Form Direc or Inc (I) (In:	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				(	Code	le V (A)		(D)	Date Exerci	sable	Expiration Date	Title	Amount or Number of Shares	1					
Stock	\$24.66	11/02/2011			M			4,000	(5)	)	12/10/2011	Commor	4,000	;	\$0.00	16,946	,	D	

## **Explanation of Responses:**

- 1. Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$37.06 (range \$36.55 to \$37.52).
- 3. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Open market sales reported on this line occurred at a weighted average price of \$37.78 (range \$37.55 to \$38.26).
- 5. Fully vested.

## Remarks:

Omar White, Attorney-In-Fact 11/03/2011

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.